CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics Holdings Limited a biopharmaceutical company engages in discovering developing and commercializing chimeric antigen receptor T CART cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States The company is involved in developing CT053 an autologous CART product candidate that is in pivotal Phase II trial for the treatment of relapsedrefractory multiple myeloma in China CT041 an autologous CART product candidate that is in Phase IbII clinical trial for advanced gastricgastroesophageal junction cancer and pancreatic cancer in China as well as in Phase Ib clinical trial for advanced gastric or pancreatic cancer in the United States and CT011 an autologous CART product candidate that is in Phase I clinical trial for patients with Glypican3 positive advanced hepatocellular carcinoma It is also developing CT032 an autologous CART products candidate that is in Phase III clinical trial for the treatment of B cell NonHodgkins lymphoma in China AB011 a humanized monoclonal antibody product candidate that is in Phase I clinical trial for the treatment of CLDN182 positive solid tumors in China and CT017 an autologous Glypican3targeted CART product candidate for the treatment of hepatocellular carcinoma as well as other product candidates for the treatment of solid tumors The company was founded in 2014 and is headquartered in Shanghai China